News|Articles|November 16, 2026

FAQ: Why CGM and insulin pump coverage is in question for type 1 diabetes patients

Listen
0:00 / 0:00

Key Takeaways

  • CMS will shift CGMs and insulin pumps into DMEPOS competitive bidding, likely consolidating suppliers sharply and reshaping distribution well before the planned 2028 full rollout.
  • Advocacy groups urge congressional delay/blocking, citing insufficient transition time, potential supplier-driven device switching, and reduced access to interoperable pump–CGM pairings.
SHOW MORE

A CMS rule moving insulin pumps and CGMs into Medicare bidding by 2028 has drawn a coalition letter and a Senate bill seeking delay.

Type 1 diabetes is an autoimmune disease with no cure. Many of the roughly 1.5 million Americans who have it rely on insulin pumps and continuous glucose monitors, or CGMs, as standard care, according to Breakthrough T1D (formerly the Juvenile Diabetes Foundation [JDRF]). That's why a new CMS rule on how Medicare pays for these devices has become one of the most closely watched fights in diabetes policy right now. This FAQ explains what's changing, who's pushing back and what it means for health plans.

1. What did CMS actually change?

CMS finalized a rule as part of its 2026 home health payment rule. The rule moves CGMs and insulin pumps into Medicare's Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) competitive bidding program. Full rollout is set for 2028. CMS itself expects the change to leave about 10 national contract suppliers for CGMs and insulin pumps—a steep drop from the much larger group of suppliers today.

2. Why are advocacy groups and lawmakers pushing back?

On Oct. 14, a coalition of 12 diabetes and endocrinology groups—including the American Diabetes Association, the American Association of Clinical Endocrinology, the Endocrine Society, T1D Exchange and Beyond Type 1—sent a letter to Congress. It went to House Energy and Commerce Committee Chair Brett Guthrie and Ranking Member Frank Pallone.

The letter asked Congress to “pass legislation that blocks or delays” the program “until CMS can ensure patient access.” It raises a few specific worries: a transition period it calls too short, the risk that “suppliers could steer patients to the diabetes device most economically favorable to the supplier” instead of the one a patient and doctor picked together, and the chance that patients could end up “unable to access CGMs and insulin pumps that are interoperable with each other.” A supplier survey cited in the letter found 47% of home-equipment suppliers expect a serious business risk from the program.

3. What practical risks could this create for people already using these devices?

David Kerr, MBChB, a diabetes and digital health physician at Sutter Health who reviewed this piece, flagged two more risks beyond the ones above. First: competitive bidding tends to favor large, high-volume mail-order suppliers over smaller, specialized diabetes equipment companies. Many patients now use automated insulin delivery systems, where a pump and a CGM work together as one connected system. If one of those devices breaks down or throws an error, a patient may no longer have a local specialist who understands how the two work together.

Instead, they could be routed to a general equipment call center that also handles things such as CPAP machines and wheelchairs, which could mean slower help exactly when a patient needs it fast.

Additionally, Kerr pointed to compatibility problems during rental transitions. These connected systems depend on the pump and the CGM software communicating with each other without any gaps. Now that both devices are billed together as one ongoing monthly rental, a billing mix-up—like a supplier billing for an older CGM sensor that doesn't match a patient's updated pump software—could break that connection. If that happens, a patient could be forced back to checking blood sugar and dosing insulin by hand until the billing issue gets sorted out.

4. What does this mean for health plans specifically?

Competitive bidding is technically a Medicare fee-for-service program. However, a smaller national supplier base could still affect Medicare Advantage plans and commercial plans too, since many of the same suppliers serve more than one type of plan, according to the letter to Congress. Plans with many type 1 diabetes members—especially children and young adults, who rely most heavily on pumps and CGMs—should watch this supplier shrinkage closely and start building a backup plan now, well ahead of the 2028 deadline. Because full rollout is still two years out, plans also have time to weigh in while Congress is still deciding what to do.

5. Is there a legislative fix in motion?

Yes, though its path forward just got more complicated as Sens. Susan Collins, R-Maine, and Jeanne Shaheen, D-N.H., who led the Senate Diabetes Caucus, introduced S. 4037, the Diabetes Interventions Addressing Barriers to Enrollment, Technology and Education Services Act, earlier this year. The bill would keep insulin pumps and CGMs out of Medicare competitive bidding for five years, expand Medicare coverage of diabetes self-management training, and direct the U.S. Department of Health and Human Services to treat automated insulin delivery algorithms as their own payable supply category.

“Their new legislation is an important step forward in protecting access to these critically important products," Tom Ryan, president and CEO of the American Association for Homecare, said when the bill was introduced.

6. What's the other major access gap in type 1 diabetes care right now?

There's a second access gap worth watching, beyond device coverage: Tzield (teplizumab), the only FDA-approved drug that can delay type 1 diabetes from becoming full-blown, or what doctors call stage 3. It works by targeting the immune attack that destroys insulin-producing cells. However, it only works in patients caught early, at stage 2 when two or more diabetes-related antibodies show up in the blood along with abnormal blood sugar, before any symptoms appear. Stage 2 carries serious risk: almost everyone who reaches it will develop full-blown type 1 diabetes eventually, and 75% will within five years.

The real problem is screening, not the drug. Most people tested for these antibodies are close relatives of someone with type 1 diabetes, found through research networks like TrialNet. Although 85% to 90% of people who later develop type 1 diabetes have no close relative with the disease, most people who could benefit from Tzield are never found in time.

“Payors are willing to pay for newborn screening, but not so much on testing 100% of kids for antibodies,” William A. Hagopian, M.D., Ph.D., director of diabetes programs at the Pacific Northwest Research Institute, said around the time of the drug's approval.

The real bottleneck for health plans to watch isn't the drug's price tag. It's getting more people screened in the first place.

This FAQ was reviewed for accuracy by Kerr.


Related to this article